Originally published In Press as doi:10.1074/jbc.C000062200 on April 3, 2000
J. Biol. Chem., Vol. 275, Issue 24, 18391-18398, June 16, 2000
The Gut-enriched Krüppel-like Factor (Krüppel-like
Factor 4) Mediates the Transactivating Effect of p53 on the
p21WAF1/Cip1 Promoter*
Weiqing
Zhang
,
Deborah E.
Geiman
,
Janiel M.
Shields
,
Duyen
T.
Dang
§,
Channing S.
Mahatan
,
Klaus H.
Kaestner¶,
Joseph R.
Biggs
,
Andrew S.
Kraft
, and
Vincent W.
Yang
**
From the Departments of
Medicine and ** Biological
Chemistry, The Johns Hopkins University School of Medicine, Baltimore,
Maryland 21205, the ¶ Department of Genetics, University of
Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, and
the
Department of Medical Oncology, University of Colorado
Health Science Center, Denver, Colorado 80262
Received for publication, January 27, 2000, and in revised form, March 17, 2000
 |
ABSTRACT |
An important mechanism by which the tumor
suppressor p53 maintains genomic stability is to induce cell cycle
arrest through activation of the cyclin-dependent kinase
inhibitor p21WAF1/Cip1 gene. We show that the gene encoding the
gut-enriched Krüppel-like factor (GKLF, KLF4) is concurrently
induced with p21WAF1/Cip1 during serum deprivation and DNA
damage elicited by methyl methanesulfonate. The increases in expression
of both Gklf and p21WAF1/Cip1 due to DNA damage are
dependent on p53. Moreover, during the first 30 min of methyl
methanesulfonate treatment, the rise in Gklf mRNA level
precedes that in p21WAF1/Cip1, suggesting that GKLF may be
involved in the induction of p21WAF1/Cip1. Indeed, GKLF
activates p21WAF1/Cip1 through a specific Sp1-like
cis-element in the p21WAF1/Cip1 proximal promoter.
The same element is also required by p53 to activate the
p21WAF1/Cip1 promoter, although p53 does not bind to it.
Potential mechanisms by which p53 activates the p21WAF1/Cip1
promoter include a physical interaction between p53 and GKLF and the
transcriptional induction of Gklf by p53. Consequently, the
two transactivators cause a synergistic induction of the
p21WAF1/Cip1 promoter activity. The physiological relevance of
GKLF in mediating p53-dependent induction of
p21WAF1/Cip1 is demonstrated by the ability of antisense
Gklf oligonucleotides to block the production of
p21WAF1/Cip1 in response to p53 activation. These findings
suggest that GKLF is an essential mediator of p53 in the
transcriptional induction of p21WAF1/Cip1 and may be part of a
novel pathway by which cellular responses to stress are modulated.
 |
INTRODUCTION |
A principal function of the tumor suppressor p53 is to maintain
genomic stability. It does so by eliciting cellular changes in response
to various forms of stress such as DNA damage, hypoxia, and nucleotide
deprivation (1-3). The amount of p53 protein increases in response to
these so-called genotoxic stresses. In addition, covalent modifications
such as phosphorylation are involved in its activation (4, 5). Once
activated, p53 exerts potent regulatory effects on diverse aspects of
cellular events that cumulate in cell cycle arrest or apoptosis (3).
Many of these "downstream" events are dependent upon the ability of
p53 to function as a transcription factor in activating the expression
of "target" genes (2, 6). Notably, an important consequence of p53
activation is the transcriptional induction of the gene encoding the
cyclin-dependent kinase
(Cdk)1 inhibitor p21 (also
called WAF1 or Cip1) (7, 8). p21WAF1/Cip1 inhibits the activity
of several cyclin-Cdk complexes such as cyclin D1-Cdk4, cyclin E1-Cdk2,
and cyclin A-Cdk2, which results in cell cycle arrest at the
G1-S transition checkpoint (9, 10).
The gut-enriched Krüppel-like factor (GKLF, KLF4) (11) is a
recently identified and developmentally regulated transcription factor,
the expression of which is enriched in the epithelial cells of the
gastrointestinal tract (12-14), skin (14, 15), and thymus (16) and in
vascular endothelial cells (17). Both the in vivo (12-16)
and in vitro (12) patterns of expression of Gklf
are indicative of a growth arrest-associated nature. Upon stimulation
of quiescent cultured cells by fresh serum, levels of Gklf
mRNA are decreased significantly during the G1-S
transition phase of the cell cycle (12). Conversely, constitutive
expression of GKLF inhibits DNA synthesis (12). In vivo,
Gklf transcripts are highly enriched in the population of
terminally differentiated, post-mitotic epithelial cells of the
intestinal tract and skin (12-15). Moreover, the intestinal expression
of Gklf is down-regulated in two independent mouse models of
intestinal tumorigenesis or hyperproliferation (18, 19). Taken
together, these studies suggest that GKLF is potentially a negative
regulator of proliferation; however, the mechanism by which it
accomplishes this task is not well defined.
The established binding site for GKLF is rich in GC content (20) and
overlaps with that for the transcription factor Sp1 (21, 22). By
coincidence, the proximal promoter of the p21WAF1/Cip1 gene
contains a number of GC-rich elements (7), some of which have been
shown to bind Sp1 (23-29). These Sp1-binding sites have been shown to
be important in controlling expression of p21WAF1/Cip1 in
several physiologically diverse processes, including the gene's responsiveness to phorbol ester (23), transforming growth
factor-
(24-26), and sodium butyrate (27), and in keratinocyte
differentiation (28). As both Gklf and p21WAF1/Cip1
are growth arrest-associated genes, we sought to determine whether GKLF
is involved in regulating p21WAF1/Cip1 expression. We
demonstrate that GKLF not only transactivates the p21WAF1/Cip1
proximal promoter, but also mediates the activating effects of p53 in
response to DNA damage on the same promoter. This study suggests that
GKLF may be an important component of the p53 tumor suppressor network
of regulatory proteins.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Constructs, Reagents, and Cell Lines--
The eukaryotic
expression vector PMT3 and its derivatives containing various forms of
GKLF were previously described (12, 20, 30, 31). They include
full-length GKLF (PMT3-GKLF-(1-483)), truncated GKLF lacking the three
zinc fingers (PMT3-GKLF-(1-401)), and truncated GKLF containing the
zinc fingers only (PMT3-GKLF-(350-483)). pC53-SN3 and
pC53-SX3, two cytomegalovirus-based expression constructs containing wild-type p53 and mutant p53 with a missense mutation at
codon 143 in the DNA-binding domain (DBD) of p53, respectively, were
kindly provided by B. Vogelstein and K. Kinzler (32). The reporter
constructs linking various regions of the p21WAF1/Cip1 promoter
to chloramphenicol acetyltransferase (CAT) have previously been
described (23). They include the CAT reporter linked to either a
2320-nt 5'-flanking sequence of the p21WAF1/Cip1 gene
containing an upstream p53-binding site at nt
2301 (33) or the same
2320-nt 5'-flanking sequence with a small internal deletion of the
sequence between nt
122 and
61 of the p21WAF1/Cip1 promoter
that removed the first four of the six Sp1 sites from the proximal
promoter (33). Reporter constructs containing the proximal promoter
region of the p21WAF1/Cip1 gene with various 5'-end points as
well as internal deletions or point mutations affecting the various Sp1
sites in the proximal promoters have all been described (23). The
WWP-Luc and DM-Luc constructs are two luciferase reporters that contain
2.4 and 2.2 kb, respectively, of the 5'-flanking sequence of the
p21WAF1/Cip1 gene and were kindly provided by B. Vogelstein and
K. Kinzler (7). The DM-Luc construct lacks the upstream p53-binding
site at nt
2301 in the p21WAF1/Cip1 promoter (7).
The polyclonal rabbit anti-GKLF serum was described (12). Anti-p53
serum was purchased from Santa Cruz Biotechnology (sc-6243), and the
monoclonal antibody against p21WAF1/Cip1 was purchased from
Pharmingen (SXM30). The p53
/
and
p53+/+ mouse embryo fibroblasts (MEFs) were generously
provided by L. Donehower (34). The 10(1)-p53 val135 cell line was
provided by A. Levine (35). This cell line, which was derived from the parental 10(1) cell line (36), is an immortalized murine embryo fibroblast line that lacks endogenous p53 expression, but contains a
stably transfected temperature-sensitive p53 protein, val135 (37). At
the nonpermissive temperature of 38.5 °C, p53 val135 is
transcriptionally inactive, whereas at the permissive temperature of
31.5 °C, it is transcriptionally competent (35). The sense and
antisense oligonucleotides to GKLF contain nucleotide sequences corresponding to amino acid codons 7-13 of GKLF in the sense and antisense orientations, respectively. At the center of this sequence (amino acid 10) is the second of two initiation methionine codons of
GKLF, which was felt to be in a translationally more favorable context
than the first (14). The nucleotide sequence of the antisense
oligonucleotide is 5'-GCT GAC AGC CAT GTC AGA CTC-3', and that of the
sense oligonucleotide is 5'-GAG TCT GAC ATG GCT GTC AGC-3'.
Note that the underlined sequence represents the initiation methionine
codon at amino acid 10 (12).
Conditions of Cell Treatments and Northern and Western Blot
Analyses--
For the serum deprivation experiments, the content of
fetal calf serum in the cell medium was reduced from 10 to 0.5% to
induce a growth-arrested state (12). To cause DNA damage, methyl
methanesulfonate (MMS) was added to cells at a concentration of 100 µg/ml, which has previously been shown to result in cell cycle arrest
(38). After various treatment periods, total RNA was isolated from
cells using Triazol (Life Technologies, Inc.). Twenty µg of RNA from each sample were studied by Northern blot analyses using conditions previously described (12). Blots were probed with a full-length cDNA encoding GKLF (12), p21WAF1/Cip1 (7), or
glyceraldehyde-3-phosphate dehydrogenase
(CLONTECH). The conditions for Western blot
analysis were also previously described, using a 1:1000 dilution of an
affinity-purified polyclonal anti-GKLF serum (12).
Transfection and Luciferase and CAT Assays--
All
transfections were performed by lipofection as described (20, 21, 30,
31). Unless otherwise specified, all reactions contained 5 µg each of
the reporter and effector constructs/10-cm dish. Luciferase and CAT
assays were performed as described (20, 21).
Reverse Transcription-Polymerase Chain Reactions--
RNA was
extracted from human embryonic kidney (HEK) 293 cells and human colonic
carcinoma HT29 cells (39). The content of Gklf transcript
from each cell line was determined using reverse transcription-PCR. The
content of the
-actin transcript was similarly determined as a
control. One µg of RNA was reverse-transcribed in an 80-µl volume
containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 10 mM dithiothreitol, 3 mM MgCl2,
0.5 mM dGTP, 0.5 mM dATP, 0.5 mM
dTTP, 0.5 mM dCTP, 80 units of RNase inhibitor, 100 pmol of random primer, pd(N)6, and 200 units of Moloney murine
leukemia virus reverse transcriptase (Life Technologies, Inc.) at
42 °C for 1 h. The cDNA was then amplified in a 50-µl
reaction that contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 10 mM MgCl2, 0.1% gelatin,
2.5 units of REDTaq DNA polymerase (Sigma), 0.2 mM dGTP, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM
dCTP, and 40 pM each of the forward and reverse primers
(see below) at the following settings: 94 °C for 45 s, 45 °C
for 1 min, and 72 °C for 1.5 min for a total of 40 cycles. The PCR
products were then visualized on a 1.5% agarose gel stained with
ethidium bromide.
The primers used in the PCR were synthesized according to the published
cDNA sequences encoding human GKLF and
-actin
(GenBankTM Data Bank accession numbers AF105036 and X00351,
respectively). The forward primer sequence for GKLF is
5'-AGGTCGGACCACCTCGCCTTACACATG-3', and the reverse primer sequence is
5'-AAGGTAAAGAGAATACAAGGTGATCTTTTATGC-3'. The length of the expected PCR
product was 345 bp. The forward and reverse primer sequences for
-actin are 5'-TACGCCAACACAGTGCTGTCTGG-3' and
5'-TACTCCTGCTTGCTGATCCACAT-3', respectively, with the expected PCR
product measuring 206 bp.
Electrophoretic Mobility Shift Assays--
EMSAs were performed
as described (20). Preparation of nuclear extracts from COS-1 cells
transfected with PMT3 expression constructs containing full-length
GKLF, truncated GKLF containing only the zinc fingers or lacking the
zinc fingers, or PMT3 vector alone was as described previously (20,
21). Purified p53 containing the DBD was kindly provided by N. Pavletich (40). This domain contains the core portion of p53 between
amino acids 102 and 292, which binds with high affinity to a p53
recognition site (40, 41). The purification of recombinant p53 DBD
expressed from the pET3d bacterial expression vector (Novagen) in
transformed Escherichia coli BL21(D3) cells was as described
previously (40). The protein was supplied at a concentration of 14 mg/ml in a solution of 50 mM BisTris propane HCl, pH 6.8, 200 mM sodium phosphate, and 5 mM
dithiothreitol and had a >98% purity of the core domain.
The wild-type p21 oligonucleotide used in EMSA contains the sequence
between nt
129 and
99 of the p21WAF1/Cip1 promoter, which
includes both Sp1-1 and Sp1-2 sites (27). The mutant p21
oligonucleotide contains a 3-bp substitution in the Sp1-1 site. The
sequences in the sense orientation for the two oligonucleotides are
shown below.
The oligonucleotide probe containing the binding site for p53
was derived from the p53-response sequence in the promoter of the human
GADD45 gene (42) and has the sequence
5'-TACAGAACATGTCTAAGCATGCTGGGG-3' in the sense orientation. When
indicated, unlabeled competitor oligonucleotides were added in 10-, 20-, or 50-fold molar excess of the probe to the reaction.
In Vitro Synthesis of p53 and
Immunoprecipitation--
[35S]Methionine-labeled p53 was
synthesized by the TNT Coupled Reticulocyte Lysate system (Promega)
using a full-length cDNA encoding p53 cloned in pBluescript
(provided by B. Vogelstein). Ten µl of the translation product were
mixed with 50 µg of nuclear extracts prepared from transfected COS-1
cells in a final volume of 100 µl containing 20 mM HEPES,
pH 7.5, 40 mM KCl, 3 mM MgCl2, 1 mM dithiothreitol, and 5% glycerol at 4 °C for 2 h. At the completion of the incubation, 15 µg of affinity-purified
anti-GKLF serum or preimmune serum were added to the reaction, which
was gently rotated overnight at 4 °C. Fifty µl of packed protein
A-Sepharose beads (Amersham Pharmacia Biotech) were then added to each
reaction, and the incubation was continued for 1 h at 4 °C. The
beads were subsequently collected by centrifugation, washed three times
with the incubation buffer, and resuspended in sample buffer before electrophoresis.
 |
RESULTS |
Both Gklf and p21WAF1/Cip1 Are Induced during Growth
Arrest--
Previously, we showed that the levels of the
Gklf transcript were low in actively proliferating cells,
but were increased in cells that had been deprived of serum (12).
Results of the Northern blot analysis in Fig.
1A recapitulate this event.
Fig. 1A also shows that upon serum deprivation, the levels
of the p21WAF1/Cip1 transcript rose concomitantly with those of
Gklf. To determine whether Gklf is induced during
growth arrest under a different condition, we treated NIH 3T3 cells
with MMS, which causes DNA damage and subsequently cell cycle arrest
(38). As shown in Fig. 1B, the levels of Gklf
mRNA were increased 2 h after the addition of MMS, as were
those of p21WAF1/Cip1 mRNA. When normalized to the
expression of the control glyceraldehyde-3-phosphate dehydrogenase
gene, which was not affected by the treatment, the degree of induction
of p21WAF1/Cip1 was higher than that of Gklf between
2 and 8 h of MMS treatment (Fig. 1B, bar
graph). This contrasts with the changes in mRNA levels of the
two genes during the initial 30 min of treatment, in which the rise in
Gklf preceded that in p21WAF1/Cip1 (Fig.
1C). These results suggest that both Gklf and
p21WAF1/Cip1 respond similarly to signals elicited during
growth arrest due to DNA damage. However, the induction of
Gklf begins slightly earlier than that of
p21WAF1/Cip1 during the initial phase of DNA damage.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 1.
Northern blot analysis of
Gklf and p21WAF1/Cip1 in NIH 3T3 cells during
growth arrest. Growth arrest was induced in actively proliferating
NIH 3T3 cells maintained in a medium containing 10% fetal calf serum
(FCS) by the reduction of serum content to 0.5%
(A) or by the addition of 100 µg/ml MMS to the medium
(B and C). RNA was isolated at the indicated time
points, and 20 µg were loaded in each lane and analyzed for the
message content of Gklf, p21WAF1/Cip1, or
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The
bar graphs show the quantitative information of -fold
induction of Gklf (open bars) and
p21WAF1/Cip1 (closed bars) at each treatment time
point over the untreated (Basal) value for each experiment.
The calculation was performed first by normalizing the band intensity
of the Gklf or p21WAF1/Cip1 transcript to that of
glyceraldehyde-3-phosphate dehydrogenase at each time point and then
comparing the normalized value of Gklf or
p21WAF1/Cip1 at each treatment time point with that of
untreated cells (time 0).
|
|
Induction of GKLF and p21WAF1/Cip1 by MMS Is Dependent
on p53--
To determine whether the inductive responses of
Gklf and p21WAF1/Cip1 to MMS treatment are dependent
on p53, we compared the expression of the two genes in MEFs isolated
from mice that contained (p53+/+) or lacked
(p53
/
) p53 created by homologous
recombination (34). As shown in Fig. 2
(lanes 1 and 2), neither fibroblasts contained
appreciable amounts of GKLF and p21WAF1/Cip1 in the untreated
state, despite a relative abundance of p53 in the p53+/+
cells. Upon the addition of MMS, there was a dramatic increase in the
levels of GKLF and p21WAF1/Cip1 beginning at 2 h but, only
in p53+/+ MEFs (lanes 4, 6, and
8). In contrast, although there was a p53-independent response in GKLF and p21WAF1/Cip1 production to MMS in
p53
/
cells (lanes 3,
5, and 7), this component appeared minor compared with the p53-proficient cells. We conclude that the increase in expression of Gklf in response to MMS-induced DNA damage,
like that of p21WAF1/Cip1, is dependent on the presence of
p53.

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 2.
Western blot analysis of GKLF and
p21WAF1/Cip1 in MEFs proficient or deficient in p53. MEFs
were prepared from p53-deficient ( / ) mouse embryos (34) or their
wild-type littermate control (+/+) and treated with 100 µg/ml MMS for
the time periods indicated. Proteins were isolated and analyzed for the
content of p53, GKLF, or p21WAF1/Cip1 by Western blot analysis.
Load represents a portion of the gel stained with Coomassie
Blue before electrophoretic transfer.
|
|
Both GKLF and p53 Transactivate the p21WAF1/Cip1
Proximal Promoter through an Identical cis-Element--
The sequential
pattern of expression in Gklf followed by
p21WAF1/Cip1 immediately after the addition of MMS raised the
intriguing question of whether GKLF might be responsible in part for
the induction of p21WAF1/Cip1. We considered this plausible, as
the promoter of the p21WAF1/Cip1 gene contains a number of
GC-rich cis-elements that resemble Sp1-binding sites (7,
23-29), and GKLF has been shown to bind to a GC-rich DNA sequence with
which Sp1 also interacts (20, 21).
To determine whether GKLF regulates the p21WAF1/Cip1 promoter,
we performed cotransfection experiments in HEK 293 cells using a series of p21WAF1/Cip1 promoter-reporter constructs (23) and an
expression construct containing either wild-type GKLF or mutant GKLF
with its zinc fingers deleted (Fig.
3A, effectors 2 and
3, respectively) (12, 20, 30, 31). Since p53 has been shown
to transcriptionally activate a reporter gene when linked to the
5'-flanking sequence of p21WAF1/Cip1 (7, 23), expression
constructs containing wild-type p53 or mutant p53 that lost its ability
to bind DNA (Fig. 3A, effectors 4 and
5, respectively) (32) were also included in the analysis. Consistent with a previous report (13), HEK 293 cells contained a
negligible amount of Gklf transcript at the base-line level as determined by reverse transcription-PCR relative to a human colon
cancer carcinoma cell line, HT29 (Fig. 3L). This low level of base-line Gklf expression in HEK 293 cells allowed a
better delineation of the effects of GKLF on the p21WAF1/Cip1
promoter activity.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 3.
GKLF and p53 transactivate the
p21WAF1/Cip1 promoter. A
depicts the five effectors used throughout the cotransfection studies.
Effector 1 is the PMT3 expression vector alone.
Effectors 2 and 4 are expression constructs of
wild-type GKLF and p53, respectively. Effector 3 is a mutant
GKLF that does not have its zinc fingers (ZF) (30).
Effector 5 is a mutant p53 with a missense mutation at codon
143 (X) in the DBD of p53 (32). Various regions of the
p21WAF1/Cip1 promoter were linked to the CAT reporter
(B-K) and cotransfected with an equivalent quantity of the
various effectors into HEK 293 cells. The four Sp1-binding sites (27)
between nt 122 and 61 of the promoter are represented by the
four arrowheads. The locations for Sp1-1 and Sp1-2 are
identified in D. The × in J and
K represents a 3-bp mutation in the first and second
Sp1-binding sites, respectively. The numbers on the
x axis in D-K correspond to the five
effectors shown in A. C is the substrate
chloramphenicol, and AC represents the acetylated product.
% Conversion = (AC/(AC + C)) × 100. Shown in D-K are the means of three independent
experiments. Bars represent S.D. L shows the
results of reverse transcription-PCR of the mRNA levels of
Gklf and -actin in HT29 and HEK 293 cells.
|
|
Fig. 3B shows that both wild-type GKLF and p53
(effectors 2 and 4, respectively), but not mutant
GKLF and p53 (effectors 3 and 5, respectively),
transactivated the CAT reporter gene linked to nt
2320 to +16 of the
p21WAF1/Cip1 promoter sequence. However, neither wild-type GKLF
nor wild-type p53 was able to transactivate the same promoter that had
a small internal deletion in the sequence between nt
122 and
61
(Fig. 3C). These results indicate that GKLF, like p53, is
capable of activating the p21WAF1/Cip1 promoter and that in
order for both proteins to act on the promoter, the sequence between nt
122 and
61 is essential. The dependence of p53 on this proximal
region of the p21WAF1/Cip1 promoter was unexpected since the
binding sites for p53 in 2320 nt of the promoter were previously
localized to sequences much farther upstream from the immediate
flanking region of the p21WAF1/Cip1 gene (43).
The sequence between nt
122 and
61 of the p21WAF1/Cip1
promoter contains four GC-rich elements that resemble Sp1-binding
sites, which have previously been designated Sp1-1 to Sp1-4 sites in
the 5' to 3' direction (27). To precisely define the
cis-element(s) within this sequence that mediates the
activating effect of GKLF and p53 on the p21WAF1/Cip1 promoter,
we performed additional cotransfection experiments in which the CAT
reporter gene was linked to either
154 to +16 bp of the promoter
(Fig. 3D) or to one that contained various 5'- and internal
deletions or point mutations (Fig. 3, E-K). It is clear
from the results of these experiments that the transactivating effects
of GKLF and p53 were co-localized to an identical
cis-element, which was the first Sp1-binding site (Sp1-1
site) beginning at nt
116 in the p21WAF1/Cip1 promoter.
GKLF, but Not p53, Binds to the Sp1-1 Element in the
p21WAF1/Cip1 Promoter--
To determine whether GKLF or
p53 binds to the Sp1-1 sequence identified above, we performed EMSAs
between GKLF and a labeled oligonucleotide containing the sequence
between nt
129 and
99 of the p21WAF1/Cip1 promoter (Fig.
4A, p21 (wt) Probe)
or between the DBD of p53 (40, 41) and an established p53-binding
sequence (Fig. 4B, p53 Probe). Nuclear
extracts prepared from COS-1 cells transfected with the PMT3 expression
vector containing either full-length (FL) GKLF (Fig.
4A, lane 1) or the zinc finger (ZF)
portion of GKLF (lane 9) bound to the wild-type p21 probe.
The resulting DNA-protein complexes (C1 and C2)
were competed away by an unlabeled wild-type p21WAF1/Cip1
sequence (Fig. 4A, lanes 2-4 and
10-12, respectively), but not by a mutated competitor in
which the Sp1-1 site was destroyed due to a 3-bp substitution
(lanes 5-7 and 13-15, respectively). As
controls, nuclear extracts prepared from either vector
alone-transfected cells (C, lane 16) or cells
transfected with a mutant GKLF construct lacking the zinc fingers
(
ZF, lane 17) did not exhibit any
appreciable binding to the wild-type p21 probe. The results in Fig.
4A therefore provide strong evidence that GKLF interacts
directly with the Sp1-1 site of the p21WAF1/Cip1 promoter. In
contrast, the DNA-binding domain of p53, although clearly capable of
binding to an established p53-binding sequence (Fig. 4B,
lane 2), failed to interact with the p21WAF1/Cip1
sequence since an unlabeled wild-type p21 probe did not compete at all
(lanes 6-8). Moreover, p53 DBD failed to form a complex with a labeled wild-type p21 oligonucleotide (data not shown). These
results suggest that although the transactivating effect of p53 on the
p21WAF1/Cip1 proximal promoter depends on the Sp1-1 site, as
does GKLF, it is mediated by a mechanism that does not involve the
direct binding of p53 to the DNA.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 4.
Relationship among p53, GKLF, and the Sp1-1
site of the p21WAF1/Cip1 promoter. A, GKLF
binds to the Sp1-1 site. EMSAs were performed using nuclear extracts
prepared from COS-1 cells transfected with an expression construct
containing the full-length (FL) GKLF (lanes 1-7)
or the zinc finger (ZF) region of GKLF (lanes
9-15) and a radiolabeled oligonucleotide probe containing the
sequence between nt 129 and 99 of the p21WAF1/Cip1
promoter, which includes both Sp1-1 and Sp1-2 sites (27). Where
indicated, increasing amounts of unlabeled oligonucleotides
representing either the wild-type (wt) sequence or a mutated
(mut) sequence that contains a 3-bp substitution in the
Sp1-1 site were included. Lane 8 contains the probe alone
without added proteins. Lanes 16 and 17 contain
nuclear extracts obtained from COS-1 cells transfected with the PMT3
vector alone (C) and the GKLF construct that lacks the zinc
fingers ( ZF) as in Fig. 3A,
respectively. C1 is the complex formed between full-length
GKLF and the probe, and C2 is formed between the zinc
fingers and the probe. F is free probe. B, p53
does not interact with the sequence between nt 129 and 99 of the
p21WAF1/Cip1 promoter. EMSAs were performed with the purified
DBD of p53 (40) and a labeled probe representing an established
p53-binding site. Competitors include unlabeled p53-binding sequence
(lanes 3-5) and unlabeled wild-type p21WAF1/Cip1
sequence between nt 129 and 99 (lanes 6-8).
C3 indicates the complex between p53 DBD and the probe.
C, GKLF interacts with p53. 35S-Labeled p53
synthesized by in vitro transcription and translation was
mixed with nuclear extracts from COS-1 cells transfected with
PMT3-GKLF(ZF), PMT3-GKLF(FL), or PMT3 vector alone and precipitated
with either preimmune (PI) serum or anti-GKLF serum
( ). Lane 1 (*) contains the input p53, and
lane 2 is p53 mixed with protein A-Sepharose beads without added serum.
The precipitated materials were resolved by denaturing polyacrylamide
gel electrophoresis and visualized by autoradiography. D,
p53 transactivates the Gklf promoter. Either 5.0 or 1.0 kb
of the 5'-flanking sequence of the mouse Gklf gene was
linked to a luciferase reporter and cotransfected into Chinese hamster
ovary cells with an expression construct containing either wild-type
p53 or mutant p53 that no longer binds DNA (see Fig. 3A).
Included was a p21 WWP-Luc construct containing 2.4 kb of the
p21WAF1/Cip1 promoter sequence linked to the luciferase
reporter as a control (7). Shown are the means of four experiments.
Bars are S.D.
|
|
p53 Physically Interacts with GKLF and Transcriptionally Activates
the GKLF Promoter, Resulting in a Synergistic Activation of the
p21WAF1/Cip1 Promoter by p53 and GKLF--
One potential
method by which p53 may accomplish its indirect effect on the
p21WAF1/Cip1 proximal promoter is by forming a physical complex
with GKLF, thus gaining access to the promoter. To test this
hypothesis, we performed co-immunoprecipitation experiments using
in vitro synthesized p53 and GKLF produced in transfected
cells. As shown in Fig. 4C, anti-GKLF serum (
)
specifically coprecipitated p53 when p53 was combined with nuclear
extracts from cells transfected with either the zinc finger region of
GKLF (lane 6) or full-length GKLF (lane 7), but
not with those transfected with the PMT3 vector alone (lane
8). No p53 was detected in any of the reactions incubated with
preimmune (PI) serum (Fig. 4C, lanes
3-5). These findings provide strong evidence for a physical
interaction between p53 and GKLF in a region that includes the zinc
fingers of GKLF. It is of interest to note that only full-length p53,
but not an internally initiated p53 with an estimated molecular mass of
40 kDa (Fig. 4C, lane 1), was recovered in the
immunoprecipitates (lanes 6 and 7). This suggests
that the N-terminal portion of p53 may be necessary for the interaction
with GKLF.
The dependence of Gklf induction on p53 as shown in Fig. 2
suggests that Gklf, like p21WAF1/Cip1, is regulated
by p53 during DNA damage. Indeed, the results in Fig. 4D
show that p53 transcriptionally activated Gklf since a luciferase reporter linked to 5.0 kb (bar 1), but not 1.0 kb
(bar 3), of the mouse Gklf promoter
was transactivated by wild-type p53. In contrast, a mutant p53 failed
to activate either reporter (Fig. 4D, bars 2 and
4). The degree of induction of the
5.0-kb Gklf
promoter activity by p53 was comparable to that seen for 2.4 kb of the
p21WAF1/Cip1 promoter (p21 WWP-Luc) (Fig. 4D,
compare bars 1 and 5). These results therefore
suggest that there is a p53-response element(s) between
5.0 and
1.0
kb of the Gklf promoter. The exact location of this
element(s) has not been determined since only the first kb of the
Gklf promoter has been sequenced so far (22) and does not
contain a p53-binding site.
To determine whether the physical interaction between GKLF and p53 and
the transcriptional induction of Gklf by p53 are
physiologically relevant to the regulation of the p21WAF1/Cip1
promoter, we performed cotransfection experiments using subsaturating concentrations of expression vectors containing GKLF, p53, or both and
a luciferase reporter gene containing 2.4 kb (WWP-Luc) or 2.2 kb
(DM-Luc) of the p21WAF1/Cip1 promoter sequence (7). The two
reporters differed from each other in that WWP-Luc included an upstream
p53-binding site located at nt
2301 (33). As shown in Fig.
5, the combination of GKLF and p53
resulted in a synergistic induction of the p21WAF1/Cip1
promoter either in the presence (bar 3) or absence
(bar 6) of the upstream p53-binding sequence. These results
suggest that GKLF and p53 act in a cooperative manner to activate
p21WAF1/Cip1 gene expression by a mechanism that does not
require the upstream p53-binding site of the p21WAF1/Cip1
promoter.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 5.
Synergistic activation of the
p21WAF1/Cip1 promoter by GKLF and p53.
Cotransfection experiments were performed in HEK 293 cells with a
luciferase reporter linked to 2.4 or 2.2 kb of the p21WAF1/Cip1
promoter sequence (WWP-Luc, which contains an upstream p53-binding site
at nt 2301, or DM-Luc, which does not, respectively (7 and 33)) and
subsaturating amounts of expression constructs containing GKLF, p53, or
both. Shown are the means of four independent experiments.
Bars represent S.D.
|
|
GKLF Is Necessary for the Inductive Effect of p53 on the
p21WAF1/Cip1 Promoter--
The sequential induction of
Gklf and p21WAF1/Cip1 during the early phase of DNA
damage and the physical dependence of p53 on GKLF in activating the
p21WAF1/Cip1 proximal promoter raised the possibility that GKLF
may be important in mediating the effect of p53 on stimulating
p21WAF1/Cip1 gene expression. To address this possibility, we
examined a system in which activation of p53 is inducible due to a
temperature-sensitive mutation. As shown in Fig.
6A, induction of wild-type p53
activity by shifting 10(1) cells stably transfected with the
temperature-sensitive p53 val135 (35, 37) from the nonpermissive
(38.5 °C) to the permissive (31.5 °C) temperature resulted in a
considerable accumulation of GKLF as well as p21WAF1/Cip1 to a
degree similar to that observed in MMS-treated p53+/+ MEFs
(Fig. 2). Next, to assess the role of GKLF in mediating the inductive
effect of p53 on p21WAF1/Cip1 expression, we treated cells with
a 21-nt antisense oligonucleotide containing the sequence that
surrounds the initiation methionine codon of GKLF in an attempt to
block the translation of Gklf mRNA. We then determined
the effects of such treatments on the production of
p21WAF1/Cip1 at the permissive temperature. A sense
oligonucleotide with the complementary sequence to the antisense
oligonucleotide was used as a control. As shown in Fig. 6B
(lanes 3, 5, and 7), cells treated with increasing concentrations of the antisense oligonucleotide contained progressively lower levels of GKLF. Importantly, the same
cells produced correspondingly lower levels of p21WAF1/Cip1 as
well. Although there was some decrease in the levels of GKLF (and
consequently, p21WAF1/Cip1) in cells treated with the highest
concentration (3.0 µM) of the control sense
oligonucleotide (Fig. 6B, lane 6), this was probably due to a nonspecific, perhaps toxic side effect of the high
oligonucleotide concentration. Be that as it may, the results in Fig.
6B indicate that a decreased production of GKLF leads to an
inhibition of p21WAF1/Cip1 synthesis. We therefore conclude
that GKLF is an important mediator of the action of p53 in inducing
p21WAF1/Cip1 gene expression.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 6.
GKLF mediates the inductive effect of p53 on
p21WAF1/Cip1. A, induction of Gklf and
p21WAF1/Cip1 in 10(1) cells (36) containing a
temperature-sensitive mutant p53 protein. 10(1) cells stably expressing
the temperature-sensitive p53 val135 mutant (35, 37) were propagated at
either the nonpermissive temperature of 38.5 °C or the permissive
temperature of 31.5 °C for the time periods indicated. Proteins were
harvested and analyzed for p53, GKLF, or p21WAF1/Cip1 by
Western blot analysis. Both GKLF and p21WAF1/Cip1 were absent
at time 0 when cells were maintained at 38.5 °C (data not shown).
B, inhibition of p21WAF1/Cip1 formation in the
10(1)-p53 val135 cell line by antisense oligonucleotides to GKLF. Cells
were transfected by lipofection with increasing amounts of sense
(S) or antisense (AS) oligonucleotides to GKLF at
38.5 °C for 5 h and shifted to 31.5 °C for an additional
24 h before being harvested for quantification of p53, GKLF, or
p21WAF1/Cip1 by Western blot analysis.
|
|
 |
DISCUSSION |
This study reveals a novel mechanism by which expression of the
p21WAF1/Cip1 gene is modulated during cellular stress induced
by DNA damage. At lease five lines of evidence in the study suggest
that GKLF plays a physiologically relevant and possibly crucial role in mediating the activating effect of p53 on p21WAF1/Cip1
expression: 1) the sequential manner in which Gklf and
p21WAF1/Cip1 are expressed in the immediate period following
DNA damage (Fig. 1C); 2) the requirement of the
GKLF-response element in the p21WAF1/Cip1 promoter
(i.e. the Sp1-1 site) for the transactivating effect of p53,
despite the presence of other bona fide p53-response
elements in the same promoter (Fig. 3, B and C);
3) the physical interaction between p53 and GKLF (Fig. 4C)
and the transcriptional induction of Gklf by p53 (Fig.
4D); 4) the cooperative manner in which GKLF and p53
activate the p21WAF1/Cip1 promoter (Fig. 5); and 5) the ability
of antisense GKLF oligonucleotides to inhibit p21WAF1/Cip1
synthesis upon p53 activation (Fig. 6). These findings demonstrate that
p53 may depend on GKLF to activate the p21WAF1/Cip1 promoter,
thus implicating GKLF as an important component of the p53 network of
cell cycle regulators.
Based on the observations of this study, we propose a model that
portrays the regulation of the p21WAF1/Cip1 proximal promoter
by GKLF and p53 during cellular stress elicited by DNA damage. In this
model, activation of p53 represents an immediate response to DNA damage
as depicted by numerous previous studies (reviewed in Refs. 1-3). The
activated p53 causes an increase in the quantity of GKLF, which is
mediated, at least in part, at the level of transcription (Fig.
4D). In addition, p53 physically interacts with GKLF and
consequently allows it to gain access to the p21WAF1/Cip1
proximal promoter through the Sp1-1 site to which GKLF alone binds. A
result of this complex relationship is the synergistic induction of the
activity of the p21WAF1/Cip1 promoter (Fig. 5). This model
would therefore predict an immediate and possibly maximal induction of
expression of the gene encoding p21WAF1/Cip1 following DNA
damage. This would assure the immediate cessation of cell cycle
progression due to the potent inhibitory effect of p21WAF1/Cip1
on cyclin-dependent kinases (48). It is of note that
despite the involvement of the various Sp1 elements in the
p21WAF1/Cip1 promoter in mediating the responses of the
promoter to numerous other physiological stimuli (Fig.
7), the lone utilization of the Sp1-1
site by GKLF and consequently by p53 has not previously been
documented.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Model for the regulation of the
p21WAF1/Cip1 proximal promoter by p53 and GKLF. The
locations of the six Sp1-like elements within 154 bp of the
p21WAF1/Cip1 promoter are designated according to a previous
report (27). The model illustrates that the activation of p53 by DNA
damage leads to both an increase in GKLF synthesis and an interaction
between p53 and GKLF (double arrow), which cumulates in the
binding of GKLF to the Sp1-1 element of the p21WAF1/Cip1
promoter. The various Sp1 cis-elements that mediate the
functions of other physiological stimuli are also indicated. They
include the phorbol ester phorbol 12-myristate 13-acetate
(PMA) and okadaic acid (OA) (23); trapoxin
(TPX), a histone deacetylase inhibitor (44);
BRCA1, the breast cancer tumor suppressor gene (45);
transforming growth factor- (TGF- ) (24);
Ca2+, which is important in keratinocyte differentiation
(28); a geranylgeranyltransferase I (GGTI) inhibitor (46);
butyrate (27) and trichostatin A (TSA) (29), both also
histone deacetylase inhibitors; levostatin, a
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (47); and
progesterone (43).
|
|
The mechanism by which GKLF participates in the regulation of the
p21WAF1/Cip1 promoter by p53 is reminiscent of that for another
growth arrest-associated gene, GADD45 (49). Like
Gklf and p21WAF1/Cip1, expression of
GADD45 is induced by genotoxic stresses such as DNA damage
(50). In addition to a strong p53-binding element in an intronic
sequence of GADD45 (42), p53 was shown to contribute to the
stress response of the GADD45 promoter (50). Much of this
stress responsiveness was localized to a GC-rich motif of the proximal
promoter to which the tumor suppressor WT1 (Wilms' tumor 1) (52) binds, but p53 does not. The
mechanism by which p53 activates the promoter is thought to be mediated
by its ability to physically interact with WT1 (50). This resulted in a
strong and cooperative induction of the GADD45 promoter when
p53 and WT1 were concurrently introduced (50). Finally, abrogation of WT1 function by an antisense vector markedly reduced the induction of
the GADD45 promoter (50). Similar to the conclusion of the present study, it was concluded that p53 contributes to the positive regulation of the GADD45 promoter primarily by
protein-protein interactions.
Recent literature provides another example in which the
p21WAF1/Cip1 promoter can be cooperatively regulated by
multiple proteins with important functions in cell cycle control. In a
previous study (45), BRCA1 was shown to transactivate the
p21WAF1/Cip1 proximal promoter through the region between nt
117 and
93, which contains both Sp1-1 and Sp1-2 sites. This
resulted in an inhibition of progression into the S phase in cells that
overexpressed BRCA1 (45). Importantly, p53 potentiated the
BRCA1-dependent activation of the p21WAF1/Cip1
promoter by physically interacting with BRCA1 (53). Thus, it appears
that p53 activates expression of its target genes such as
p21WAF1/Cip1 and GADD45 by multiple but perhaps
interrelated mechanisms. These mechanisms include direct binding of p53
to the classical p53-response elements and indirect interaction with
non-consensus binding sites through physical contacts with other
regulatory proteins, including GKLF, WT1, and BRCA1.
Another potential mechanism responsible for the synergistic induction
of the p21WAF1/Cip1 promoter by p53 and GKLF may involve the
participation of other regulatory proteins. In this regard, both p53
(54, 55) and GKLF (31) have been shown to interact with a group of
transcriptional coactivators, including p300 and CBP (56-59). In fact,
the ability of GKLF to activate transcription is dependent on its
interaction with p300/CBP (31). Thus, it is possible to modify the
model proposed in Fig. 7 to include p300/CBP, which can serve as a
bridge between p53/GKLF and the basal transcriptional machinery such as
the TATA-binding factor and RNA polymerase II (60, 61). It is of
interest to note that p300 and CBP are enzymes that display histone
acetylase activity (62, 63) and that the activity of the
p21WAF1/Cip1 promoter is subject to regulation by compounds
that alter chromatin structure due to acetylation such as butyrate,
trichostatin A, and trapoxin (Fig. 7). Moreover, the Sp1-like
cis-elements responsible for the action of these compounds
appear to differ among one another (Fig. 7). It is formally possible
that the targets of regulation by these compounds may be unique
transcription factors that recognize the different Sp1-like elements in
the p21WAF1/Cip1 promoter.
The results in Fig. 1 indicate that both Gklf and
p21WAF1/Cip1 are induced by serum deprivation and by DNA
damage. However, the kinetics in which the two genes are induced by the
two conditions are distinctly different from each other. During the
course of serum deprivation, the extent of induction for both
Gklf and p21WAF1/Cip1 is quite similar (Fig.
1A). However, the time course of induction for
Gklf and p21WAF1/Cip1 in cells treated with MMS is
different from that of serum deprivation. Thus, with the exception of
an earlier induction of Gklf during the initial 30 min of
MMS treatment (Fig. 1C), the level of induction of
p21WAF1/Cip1 after 1 h of MMS treatment is significantly
higher than that of Gklf (Fig. 1, B and
C). These results suggest that factors in addition to GKLF
may be involved in the rise in p21WAF1/Cip1 transcript level
after the immediate phase of DNA damage. However, the parallel rise in
the levels of both Gklf and p21WAF1/Cip1
transcripts during serum deprivation suggests a potentially more uniform mechanism of induction of the two genes, perhaps including a
mechanism that is independent of p53, as has been demonstrated in other
systems (64). Experiments are in progress to address this potentially
p53-independent component of Gklf and p21WAF1/Cip1 activation.
In the intestinal tract, the Gklf transcript is detected
primarily in terminally differentiated, post-mitotic epithelial cells (12-14). Interestingly, the p21WAF1/Cip1 transcript is also
distributed in the same cell population (65). Moreover, the intestinal
expression of p21WAF1/Cip1 both during development and in the
adult mouse has been shown to be independent of p53 under basal
conditions (51). Whether the in vivo expression of
Gklf is also independent of p53 is unclear at this point.
However, it is clear that the induction of both Gklf and
p21WAF1/Cip1 in response to genotoxic stress is highly
dependent on p53 (Fig. 2). Moreover, this inductive response is not
limited to the intestinal cell lineage and includes fibroblasts such as
NIH 3T3 and MEFs. Thus, the in vitro behavior of
Gklf as modulated by stress is more ubiquitous than its
in vivo tissue distribution. This may be viewed as
additional evidence for the potentially broader significance of GKLF in
mediating the "guardian" function of p53.
 |
ACKNOWLEDGEMENTS |
We thank B. Vogelstein, K. Kinzler, A. Levine, L. Donehower, and N. Palvetich for providing plasmids,
reagents, and cell lines.
 |
FOOTNOTES |
*
This work was in part supported by grants from the National
Institutes of Health (to V. W. Y., K. H. K., and A. S. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by a National Research Service Award from the National
Institutes of Health.

To whom correspondence should be addressed: Dept. of Medicine,
Ross 918, The Johns Hopkins University School of Medicine, 720 Rutland
Ave., Baltimore, MD 21205. Tel.: 410-955-9691; Fax: 410-955-9677;
E-mail: vyang@welch.jhu.edu.
Published, JBC Papers in Press, April 3, 2000, DOI 10.1074/jbc.C000062200
 |
ABBREVIATIONS |
The abbreviations used are:
Cdk, cyclin-dependent kinase;
GKLF, gut-enriched
Krüppel-like factor;
KLF4, Krüppel-like factor 4;
DBD, DNA-binding domain;
CAT, chloramphenicol acetyltransferase;
nt, nucleotide(s);
kb, kilobase(s);
bp, base pair(s);
MEFs, mouse embryo
fibroblasts;
MMS, methyl methanesulfonate;
PCR, polymerase chain
reaction;
HEK, human embryonic kidney;
EMSA, electrophoretic mobility
shift assay;
BisTris propane, 1,3-bis]tris(hydroxymethyl)methylamino[propane;
CBP, cAMP-response
element-binding protein-binding protein.
 |
REFERENCES |
| 1.
|
Agarwal, M. L.,
Taylor, W. R.,
Chernov, M. V.,
Chernova, O. B.,
and Stark, G. R.
(1998)
J. Biol. Chem.
273,
1-4
|
| 2.
|
Ko, L. J.,
and Prives, C.
(1996)
Genes Dev.
10,
1054-1072
|
| 3.
|
Levine, A. J.
(1997)
Cell
88,
323-331
|
| 4.
|
Giaccia, A. J.,
and Kastan, M. B.
(1998)
Genes Dev.
12,
2973-2983
|
| 5.
|
Prives, C.
(1998)
Cell
95,
5-8
|
| 6.
|
El-Deiry, W. S.
(1998)
Semin. Cancer Biol.
8,
345-357
|
| 7.
|
El-Deiry, W. S.,
Tokino, T.,
Velculescu, V. E.,
Levy, D. B.,
Parsons, R.,
Trent, J. M.,
Lin, D.,
Mercer, W. E.,
Kinzler, K. W.,
and Vogelstein, B.
(1993)
Cell
75,
817-825
|
| 8.
|
Harper, J. W.,
Adami, G. R.,
Wei, N.,
Keyomarsi, K.,
and Elledge, S. J.
(1993)
Cell
75,
805-816
|
| 9.
|
Hartwell, L. H.,
and Kastan, M. B.
(1994)
Science
266,
1821-1828
|
| 10.
|
Sherr, C. J.,
and Roberts, J. M.
(1995)
Genes Dev.
9,
1149-1163
|
| 11.
|
Turner, J.,
and Crossley, M.
(1999)
Trends Biochem. Sci.
24,
236-240
|
| 12.
|
Shields, J. M.,
Christy, R. J.,
and Yang, V. W.
(1996)
J. Biol. Chem.
271,
20009-20017
|
| 13.
|
Jenkins, T. D.,
Opitz, O. G.,
Okano, J.,
and Rustgi, A. K.
(1998)
J. Biol. Chem.
273,
10747-10754
|
| 14.
|
Garrett-Sinha, L. A.,
Eberspaecher, H.,
Seldin, M. F.,
and de Crombrugghe, B.
(1996)
J. Biol. Chem.
271,
31384-31390
|
| 15.
|
Segre, J. A.,
Bauer, C.,
and Fuchs, E.
(1999)
Nat. Genet.
22,
356-360
|
| 16.
|
Panigada, M.,
Porcellini, M.,
Sutti, F.,
Doneda, L.,
Pozzoli, O.,
Consalez, G. G.,
Guttinger, M.,
and Grassi, F.
(1999)
Mech. Dev.
81,
103-113
|
| 17.
|
Yet, S. F.,
McA'Nulty, M. M.,
Folta, S. C.,
Yen, H. W.,
Yoshizumi, M.,
Hsieh, C. M.,
Layne, M. D.,
Chin, M. T.,
Wang, H.,
Perrella, M. A.,
Jain, M. K.,
and Lee, M. E.
(1998)
J. Biol. Chem.
273,
1026-1031
|
| 18.
|
Ton-That, H.,
Kaestner, K. H.,
Shields, J. M.,
Mahatanankoon, C. S.,
and Yang, V. W.
(1997)
FEBS Lett.
419,
239-243
|
| 19.
|
Kaestner, K. H.,
Silberg, D. G.,
Traber, P. G.,
and Schutz, G.
(1997)
Genes Dev.
11,
1583-1595
|
| 20.
|
Shields, J. M.,
and Yang, V. W.
(1998)
Nucleic Acids Res.
26,
796-802
|
| 21.
|
Zhang, W.,
Shields, J. M.,
Sogawa, K.,
Fujii-Kuriyama, Y.,
and Yang, V. W.
(1998)
J. Biol. Chem.
273,
17917-17925
|
| 22.
|
Mahatan, C. S.,
Kaestner, K. H.,
Geiman, D. E.,
and Yang, V. W.
(1999)
Nucleic Acids Res.
27,
4562-4569
|
| 23.
|
Biggs, J. R.,
Kudlow, J. E.,
and Kraft, A. S.
(1996)
J. Biol. Chem.
271,
901-906
|
| 24.
|
Datto, M. B., Yu, Y.,
and Wang, X. F.
(1995)
J. Biol. Chem.
270,
28623-28628
|
| 25.
|
Li, J. M.,
Datto, M. B.,
Shen, X.,
Hu, P. P., Yu, Y.,
and Wang, X. F.
(1998)
Nucleic Acids Res.
26,
2449-2456
|
| 26.
|
Moustakas, A.,
and Kardassis, D.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6733-6738
|
| 27.
|
Nakano, K.,
Mizuno, T.,
Sowa, Y.,
Orita, T.,
Yoshino, T.,
Okuyama, Y.,
Fujita, T.,
Ohtani-Fujita, N.,
Matsukawa, Y.,
Tokino, T.,
Yamagishi, H.,
Oka, T.,
Nomura, H.,
and Sakai, T.
(1997)
J. Biol. Chem.
272,
22199-22206
|
| 28.
|
Prowse, D. M.,
Bolgan, L.,
Molnar, A.,
and Dotto, G. P.
(1997)
J. Biol. Chem.
272,
1308-1314
|
| 29.
|
Sowa, Y.,
Orita, T.,
Minamikawa, S.,
Nakano, K.,
Mizuno, T.,
Nomura, H.,
and Sakai, T.
(1997)
Biochem. Biophys. Res. Commun.
241,
142-150
|
| 30.
|
Shields, J. M.,
and Yang, V. W.
(1997)
J. Biol. Chem.
272,
18504-18507
|
| 31.
|
Geiman, D. E.,
Ton-That, H.,
Johnson, J. M.,
and Yang, V. W.
(2000)
Nucleic Acids Res.
28,
1106-1113
|
| 32.
|
Baker, S. J.,
Markowitz, S.,
Fearon, E. R.,
Willson, J. K.,
and Vogelstein, B.
(1990)
Science
249,
912-915
|
| 33.
|
Gartel, A. L.,
and Tyner, A. L.
(1999)
Exp. Cell Res.
246,
280-289
|
| 34.
|
Jones, S. N.,
Sands, A. T.,
Hancock, A. R.,
Vogel, H.,
Donehower, L. A.,
Linke, S. P.,
Wahl, G. M.,
and Bradley, A.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14106-14111
|
| 35.
|
Sabbatini, P.,
Lin, J.,
Levine, A. J.,
and White, E.
(1995)
Genes Dev.
9,
2184-2192
|
| 36.
|
Harvey, D. M.,
and Levine, A. J.
(1991)
Genes Dev.
5,
2375-2385
|
| 37.
|
Wu, X.,
Bayle, J. H.,
Olson, D.,
and Levine, A. J.
(1993)
Genes Dev.
7,
1126-1132
|
| 38.
|
Fornace, A. J.,
Alamo, I.,
and Hollander, M. C.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
8800-8804
|
| 39.
|
von Kleist, S.,
Chany, E.,
Burtin, P.,
King, M.,
and Fogh, J.
(1975)
J. Natl. Cancer Inst.
55,
555-560
|
| 40.
|
Pavletich, N. P.,
Chambers, K. A.,
and Pabo, C. O.
(1993)
Genes Dev.
7,
2556-2564
|
| 41.
|
Cho, Y.,
Gorina, S.,
Jeffrey, P. D.,
and Pavletich, N. P.
(1994)
Science
265,
346-355
|
| 42.
|
Hollander, M. C.,
Alamo, I.,
Jackman, J.,
Wang, M. G.,
McBride, O. W.,
and Fornace, A. J.
(1993)
J. Biol. Chem.
268,
24385-24393
|
| 43.
|
Owen, G. I.,
Richer, J. K.,
Tung, L.,
Takimoto, G.,
and Horwitz, K. B.
(1998)
J. Biol. Chem.
273,
10696-10701
|
| 44.
|
Sambucetti, L. C.,
Fischer, D. D.,
Zabludoff, S.,
Kwon, P. O.,
Chamberlin, H.,
Trogani, N.,
Xu, H.,
and Cohen, D.
(1999)
J. Biol. Chem.
274,
34940-34947
|
| 45.
|
Somasundaram, K.,
Zhang, H.,
Zeng, Y. X.,
Houvras, Y.,
Peng, Y.,
Zhang, H.,
Wu, G. S.,
Licht, J. D.,
Weber, B. L.,
and El-Deiry, W. S.
(1997)
Nature
389,
187-190
|
| 46.
|
Adnane, J.,
Bizouarn, F. A.,
Qian, Y.,
Hamilton, A. D.,
and Sebti, S. M.
(1998)
Mol. Cell. Biol.
18,
6962-6970
|
| 47.
|
Lee, S. J.,
Ha, M. J.,
Lee, J.,
Nguyen, P.,
Choi, Y. H.,
Pirnia, F.,
Kang, W. K.,
Wang, X. F.,
Kim, S. J.,
and Trepel, J. B.
(1998)
J. Biol. Chem.
273,
10618-10623
|
| 48.
|
Xiong, Y.,
Hannon, G. J.,
Zhang, H.,
Casso, D.,
Kobayashi, R.,
and Beach, D.
(1993)
Nature
366,
701-704
|
| 49.
|
Zhan, Q.,
Chen, I. T.,
Antinore, M. J.,
and Fornace, A. J., Jr.
(1998)
Mol. Cell. Biol.
18,
2768-2778
|
| 50.
|
Fornace, A. J., Jr.,
Nebert, D. W.,
Hollander, M. C.,
Luethy, J. D.,
Papathanasion, M.,
Fargnoli, J.,
and Holbrook, N. J.
(1989)
Mol. Cell. Biol.
9,
4196-4203
|
| 51.
|
Macleod, K. F.,
Sherry, N.,
Hannon, G.,
Beach, D.,
Tokino, T.,
Kinzler, K.,
Vogelstein, B.,
and Jacks, T.
(1995)
Genes Dev.
9,
935-944
|
| 52.
|
Rauscher, F. J., III,
Morris, J. F.,
Tournay, O. E.,
Cook, D. M.,
and Curran, T.
(1990)
Science
250,
1259-1262
|
| 53.
|
Zhang, H.,
Somasundaram, K.,
Peng, Y.,
Tian, H.,
Zhang, H.,
Bi, D.,
Weber, B. L.,
and El-Deiry, W. S.
(1998)
Oncogene
16,
1713-1721
|
| 54.
|
Gu, W.,
Shi, X. L.,
and Roeder, R. G.
(1997)
Nature
387,
819-823
|
| 55.
|
Lill, N. L.,
Grossman, S. R.,
Ginsberg, D.,
DeCaprio, J.,
and Livingston, D. M.
(1997)
Nature
387,
823-827
|
| 56.
|
Eckner, R.
(1996)
Biol. Chem.
377,
685-688
|
| 57.
|
Ludlow, J. W.,
and Skuse, G. R.
(1995)
Virus Res.
35,
113-121
|
| 58.
|
Chrivia, J. C.,
Kwok, R. P.,
Lamb, N.,
Hagiwara, M.,
Montminy, M. R.,
and Goodman, R. H.
(1993)
Nature
365,
855-859
|
| 59.
|
Kwok, R. P.,
Lundblad, J. R.,
Chrivia, J. C.,
Richards, J. P.,
Bachinger, H. P.,
Brennan, R. G.,
Roberts, S. G.,
Green, M. R.,
and Goodman, R. H.
(1994)
Nature
370,
223-226
|
| 60.
|
Abraham, S. E.,
Lobo, S.,
Yaciuk, P.,
Wang, H. G.,
and Moran, E.
(1993)
Oncogene
8,
1639-1647
|
| 61.
|
Neish, A. S.,
Anderson, S. F.,
Schlegel, B. P.,
Wei, W.,
and Parvin, J. D.
(1998)
Nucleic Acids Res.
26,
847-853
|
| 62.
|
Wu, C.
(1997)
J. Biol. Chem.
272,
28171-28174
|
| 63.
|
Howe, L.,
Brown, C. E.,
Lechner, T.,
and Workman, J. L.
(1999)
Crit. Rev. Eukaryotic Gene Expression
9,
231-243
|
| 64.
|
Modiano, J. F.,
Ritt, M. G.,
Wojcieszyn, J.,
and Smith, R., III
(1999)
DNA Cell Biol.
8,
357-367
|
| 65.
|
Gartel, A. L.,
Serfas, M. S.,
Gartel, M.,
Goufman, E.,
Wu, G. S.,
El-Deiry, W. S.,
and Tyner, A. L.
(1996)
Exp. Cell Res.
227,
171-181
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Tec